Recent Investment Analysts’ Ratings Updates for Harrow (HROW)

A number of firms have modified their ratings and price targets on shares of Harrow (NASDAQ: HROW) recently:

• 3/19/2026 – Harrow had its “buy” rating reaffirmed by HC Wainwright. They now have a $70.00 price target on the stock.
• 3/18/2026 – Harrow was downgraded by Nomura to “neutral”.
• 3/18/2026 – Harrow had its “buy” rating reaffirmed by BTIG Research. They now have a $63.00 price target on the stock.
• 3/4/2026 – Harrow had its price target lowered by Cantor Fitzgerald from $94.00 to $91.00. They now have an “overweight” rating on the stock.
• 3/4/2026 – Harrow had its price target raised by HC Wainwright from $69.00 to $70.00. They now have a “buy” rating on the stock.
• 3/3/2026 – Harrow had its “outperform” rating reaffirmed by William Blair.
• 3/3/2026 – Harrow was downgraded by Zacks Research from “hold” to “strong sell”.
• 2/2/2026 – Harrow was downgraded by Zacks Research from “strong-buy” to “hold”.

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.